Candriam Luxembourg S.C.A. decreased its position in C.R. Bard, Inc. (NYSE:BCR) by 9.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,745 shares of the medical instruments supplier’s stock after selling 517 shares during the period. Candriam Luxembourg S.C.A.’s holdings in C.R. Bard were worth $1,500,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Diversified Trust Co boosted its stake in shares of C.R. Bard by 8.2% in the first quarter. Diversified Trust Co now owns 987 shares of the medical instruments supplier’s stock worth $245,000 after buying an additional 75 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of C.R. Bard during the first quarter worth $1,929,000. Huntington National Bank boosted its stake in shares of C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock worth $4,079,000 after buying an additional 1,278 shares during the period. Bollard Group LLC boosted its stake in shares of C.R. Bard by 13.5% in the first quarter. Bollard Group LLC now owns 13,917 shares of the medical instruments supplier’s stock worth $3,459,000 after buying an additional 1,651 shares during the period. Finally, Granite Investment Advisors LLC boosted its stake in shares of C.R. Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock worth $8,270,000 after buying an additional 4,159 shares during the period. Hedge funds and other institutional investors own 85.32% of the company’s stock.

C.R. Bard, Inc. (NYSE:BCR) opened at 319.75 on Friday. The company’s 50-day moving average price is $319.00 and its 200 day moving average price is $283.44. The firm has a market capitalization of $23.24 billion, a price-to-earnings ratio of 41.98 and a beta of 0.59. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 EPS. Analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.

WARNING: “Candriam Luxembourg S.C.A. Has $1.50 Million Stake in C.R. Bard, Inc. (NYSE:BCR)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-has-1-50-million-stake-in-c-r-bard-inc-nysebcr/1476997.html.

A number of brokerages recently weighed in on BCR. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub cut C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. C.R. Bard currently has a consensus rating of “Hold” and a consensus price target of $285.67.

In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.